Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol
Marco Vignetti, Paola Fazi, Giuseppe Cimino, Giovanni Martinelli, Francesco Di Raimondo, Felicetto Ferrara, Giovanna Meloni, Achille Ambrosetti, Giovanni Quarta, Livio Pagano, Giovanna Rege-Cambrin, Loredana Elia, Raffaello Bertieri, Luciana Annino, Robin Foà, Michele Baccarani, Franco Mandelli, Marco Vignetti, Paola Fazi, Giuseppe Cimino, Giovanni Martinelli, Francesco Di Raimondo, Felicetto Ferrara, Giovanna Meloni, Achille Ambrosetti, Giovanni Quarta, Livio Pagano, Giovanna Rege-Cambrin, Loredana Elia, Raffaello Bertieri, Luciana Annino, Robin Foà, Michele Baccarani, Franco Mandelli
Abstract
Thirty elderly (> 60 years) Philadelphia chromosome-positive (Ph(+)) patients with acute lymphoblastic leukemia (ALL) received imatinib, 800 mg daily, associated to steroids without further chemotherapy as frontline treatment. Median age was 69 years (range, 61-83 years). Twenty-nine patients were evaluable for response and all of them obtained a hematologic complete remission, with a median BCR-ABL reduction of 2.9 and 2.0 logs in p190(+) and p210(+) cases, respectively. Most of the induction treatment did not require admission of the patients. No major toxicities occurred and the treatment was well tolerated. Median survival from diagnosis was 20 months. This study shows that elderly Ph(+) patients with ALL-often considered eligible only for palliative treatment strategies-may benefit from an imatinib-steroids protocol, which does not require chemotherapy nor a long hospitalization, is feasible, highly active, and associated with a good quality of life.
Source: PubMed